Tesamorelin
Reduce visceral fat and stimulate natural growth hormone release.
For research purposes only. These products are not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm these products will be used for legitimate research purposes.
About Tesamorelin
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue that stimulates the pituitary gland to produce and release growth hormone. It is the only FDA-approved peptide for reducing visceral adipose tissue in specific patient populations. Unlike exogenous GH, it preserves the natural pulsatile pattern of GH release.
Key Benefits
- Reduces visceral adipose tissue
- Stimulates natural GH production
- Preserves pulsatile GH release pattern
- Improves body composition without exogenous GH
Set a goal (top of the page) to see how Tesamorelin scores against it, and what the better-evidenced alternatives are.
Category Ratings
How to Take
Common Side Effects
- Arthralgia (joint pain)
- Injection site erythema and reactions
- Fluid retention / peripheral edema
- Muscle pain
- Elevated IGF-1 levels
- Glucose intolerance
Legal & Regulatory Status
Prescription required. FDA-approved as Egrifta SV only for reduction of excess abdominal fat in HIV-associated lipodystrophy — not approved for general weight loss.
Safety and regulatory details for FDA-approved compounds are drawn from the official product label via openFDA; clinical development status reflects ClinicalTrials.gov. This information is provided for research reference, is not endorsed by the FDA, and may not be complete or current.
Research & Sources
- FDA prescribing information — Egrifta (tesamorelin), via DailyMed
- Phase 3 trial: tesamorelin reduces visceral fat in HIV-lipodystrophy, NEJM (PMID 20101189)
Sources are selected for reliability (peer-reviewed literature, openFDA, ClinicalTrials.gov) but this is a research summary, not medical advice, and may not be exhaustive.
